BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 32917226)

  • 1. The combination therapy of transarterial chemoembolisation and sorafenib is the preferred palliative treatment for advanced hepatocellular carcinoma patients: a meta-analysis.
    Cheng Z; He L; Guo Y; Song Y; Song S; Zhang L
    World J Surg Oncol; 2020 Sep; 18(1):243. PubMed ID: 32917226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis.
    Zhang L; Hu P; Chen X; Bie P
    PLoS One; 2014; 9(6):e100305. PubMed ID: 24945380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Yang M; Yuan JQ; Bai M; Han GH
    Mol Biol Rep; 2014 Oct; 41(10):6575-82. PubMed ID: 25091939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Li L; Zhao W; Wang M; Hu J; Wang E; Zhao Y; Liu L
    BMC Gastroenterol; 2018 Sep; 18(1):138. PubMed ID: 30180810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
    Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH
    J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib combined with transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis and systematic review.
    Wang G; Liu Y; Zhou SF; Qiu P; Xu L; Wen P; Wen J; Xiao X
    Hepatol Int; 2016 May; 10(3):501-10. PubMed ID: 26856326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of transarterial chemoembolization plus sorafenib for early or intermediate stage hepatocellular carcinoma: A systematic review and meta-analysis of randomized controlled trials.
    Zeng J; Lv L; Mei ZC
    Clin Res Hepatol Gastroenterol; 2016 Dec; 40(6):688-697. PubMed ID: 27339594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
    Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
    BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transarterial chemoembolization plus sorafenib versus sorafenib for intermediate-advanced hepatocellular carcinoma: A meta-analysis comparing clinical outcomes.
    Xie Y; Tian H; Xiang B; Zhang Y; Liu J; Cai Z; Xiang H
    Medicine (Baltimore); 2021 Aug; 100(33):e26958. PubMed ID: 34414963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis.
    Zhang X; Wang K; Wang M; Yang G; Ye X; Wu M; Cheng S
    Oncotarget; 2017 Apr; 8(17):29416-29427. PubMed ID: 28177886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis.
    Fu QH; Zhang Q; Bai XL; Hu QD; Su W; Chen YW; Su RG; Liang TB
    J Cancer Res Clin Oncol; 2014 Aug; 140(8):1429-40. PubMed ID: 24770582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of sorafenib combined with TACE in the treatment of advanced hepatocellular carcinoma: A meta-analysis.
    Li D; Pang Y; Xu L; Xu X
    J BUON; 2021; 26(4):1355-1364. PubMed ID: 34564992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent sorafenib therapy extends the interval to subsequent TACE for patients with unresectable hepatocellular carcinoma.
    Yao X; Yan D; Zeng H; Liu D; Li H
    J Surg Oncol; 2016 May; 113(6):672-7. PubMed ID: 26989044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation.
    Peng Z; Chen S; Wei M; Lin M; Jiang C; Mei J; Li B; Wang Y; Li J; Xie X; Chen M; Qian G; Kuang M
    Radiology; 2018 May; 287(2):705-714. PubMed ID: 29390197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the Efficacy of Sorafenib on Overall Survival in Patients with Hepatocellular Carcinoma using FT Rate: A Devised Index.
    Ohki T; Kondo M; Karasawa Y; Kawamura S; Maeshima S; Kojima K; Seki M; Toda N; Shioda Y; Tagawa K
    Adv Ther; 2017 May; 34(5):1097-1108. PubMed ID: 28389996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Potential Predictors of Prognosis and Sorafenib-Associated Survival Benefits in Patients with Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization.
    He K; Yang Z; Liu X; Yang Y; Song W; Wang S; Chen Y
    Curr Oncol; 2022 Dec; 30(1):476-491. PubMed ID: 36661687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
    Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
    Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma.
    Peng S; Zhao Y; Xu F; Jia C; Xu Y; Dai C
    PLoS One; 2014; 9(12):e112530. PubMed ID: 25460347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus.
    Zhang ZH; Liu QX; Zhang W; Ma JQ; Wang JH; Luo JJ; Liu LX; Yan ZP
    World J Gastroenterol; 2017 Nov; 23(43):7735-7745. PubMed ID: 29209114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.